Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes-Reference-Cited by-同舟云学术

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

Published:2013-02-17 Issue:7 Volume:15 Page:613-621
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Heise T.¹,Seewaldt-Becker E.²,Macha S.³,Hantel S.²,Pinnetti S.²,Seman L.³,Woerle H. J.²

Affiliation:

1. Profil; Neuss; Germany

2. Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach; Germany

3. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield; CT; USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12073/fullpdf

Reference27 articles.

1. Role of chronic and acute hyperglycemia in the development of diabetes complications;Marcovecchio;Diabetes Technol Ther,2011

2. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study;Stratton;BMJ,2000

3. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies;The Emerging Risk Factors Collaboration;Lancet,2010

4. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004;Ong;Ann Epidemiol,2008

5. Redefining treatment success in type 2 diabetes mellitus: comprehensive targeting of core defects;Cefalu;Cleve Clin J Med,2009

Cited by 239 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology;Current Diabetes Reviews;2024-10

2. Empagliflozin demonstrates cytotoxicity and synergy with tamoxifen in ER-positive breast cancer cells: anti-proliferative and anti-survival effects;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-07-27

3. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2;Basic Research in Cardiology;2024-07-24

4. Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors;International Journal of Molecular Sciences;2024-06-25

5. Epidemiology of Heart Failure and the Discovery of the Cardioprotective Effects of SGLT2 Inhibitors;JACC: Heart Failure;2024-06